The diagnosis and surveillance of clear cell renal cell carcinoma (ccRCC) remains a clinical challenge. The high and specific expression of the cluster of differentiation 70 (CD70) in ccRCC makes it a ...
Prostate-specific membrane antigen (PSMA) PET is a well-established imaging tool for the evaluation of primary and recurrent prostate cancer (PCa). 177 Lu PSMA-targeted radiopharmaceutical therapy ...
Although surface-enhanced Raman scattering (SERS) spectroscopy has traditionally been used as an in vitro analytic tool, in the past few years the first reports of the feasibility of in vivo imaging ...
Increased expression of fibroblast-activating protein (FAP) in fibrous caps may contribute to progression of atherosclerotic plaques. Methods: Forty-one patients who underwent 68Ga-conjugated ...
We developed a new C-X-C chemokine receptor 4 (CXCR4)–targeting radiolabeled peptide, [68Ga]Ga/[177Lu]Lu-BL34, using a novel and potent cyclic peptide based on structure–activity relationship studies ...
The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by ...
The use of synaptic vesicle glycoprotein 2A radiotracers with PET imaging could provide a way to measure synaptic density quantitatively in living humans. 11C-UCB-J (( R ...
The U.S. Food and Drug Administration and the European Medicines Agency approved the first prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy (RPT), 177Lu-PSMA-617 ...
The 2006 National Academy of Sciences Biologic Effects of Ionizing Radiation (BEIR) VII report is a well-recognized and frequently cited source on the legitimacy of the linear no-threshold (LNT) model ...
Journal of Nuclear Medicine June 2026, jnumed.125.270791; DOI: https://doi.org/10.2967/jnumed.125.270791 ...
Fluorescence imaging is an emerging imaging technique that has shown many benefits for clinical care. Currently, the field is in rapid clinical translation, and an unprecedented number of clinical ...
Journal of Nuclear Medicine June 2026, jnumed.126.272009; DOI: https://doi.org/10.2967/jnumed.126.272009 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results